Background The last decade witnessed the emergence of several therapeutic options for
patients with chronic lymphocytic leukemia (CLL) for first-line and relapsed settings. The vast …

Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell
transplantation (alloHSCT). Treatment options for relapse have been inadequate, and the …

Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia in Europe and
North America. The disease is characterized by proliferation and accumulation of small …

Tumor-promoting inflammation and escape from immune-mediated tumor destruction have
been recognized as hallmarks of cancer, and myeloid cells are key players in these …

CD200 expression on lymphoma/CLL cells, or in CLL serum, suppresses immunity yet is
overcome by neutralizing antibody, siRNAs, or absorption of CD200 from serum. CD200 is a …

Targeted therapies have appeared as new treatment options for several disease types,
including cancer and autoimmune disorders. Of several targets, tyrosine kinases (TKs) are …

The clinical success of checkpoint inhibitors has led to a renaissance of interest in cancer
immunotherapies. In particular, the possibility of ex vivo expanding autologous lymphocytes …

Background aims Acute myeloid leukemia (AML) is classified as a hematologic malignancy
characterized by the proliferation of immature blood cells within the bone marrow (BM) …

Dendritic cell (DC) vaccines have shown great promise in generating antitumor immune
responses but have generally fallen short of producing durable cures. Determining …

2019-11-06 Assigned to IMMATICS BIOTECHNOLOGIES GMBH reassignment IMMATICS
BIOTECHNOLOGIES GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …